Encompass Health financials
$124.02+0.45%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.94B | $5.37B | $4.80B | $4.35B | $4.01B | $3.57B | $4.61B | $4.28B |
| Gross profit | $5.94B | $5.37B | $4.80B | $4.35B | $4.01B | $3.57B | $4.61B | $4.28B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $1.05B | $864.5M | $731.8M | $630.2M | $659.4M | $527.6M | $692.5M | $629.6M |
| Net income | $564.7M | $452.9M | $349.6M | $269.8M | $410.4M | $283.2M | $357.4M | $290.3M |
| Net margin | 9.5% | 8.4% | 7.3% | 6.2% | 10.2% | 7.9% | 7.8% | 6.8% |
| Diluted EPS | $5.54 | $4.46 | $3.47 | $2.70 | $4.11 | $2.85 | $3.61 | $2.92 |
| EBITDA | $1.38B | $1.16B | $1.01B | $873.8M | $879.0M | $733.4M | $911.2M | $881.3M |
| Operating cash flow | $1.18B | $1.00B | $850.8M | $705.8M | $715.8M | $704.7M | $635.3M | $762.4M |
| Free cash flow | $439.2M | $360.3M | $267.7M | $121.7M | $170.1M | $303.6M | $249.9M | $491.9M |
| Diluted shares | 102.2M | 102.2M | 101.3M | 100.4M | 100.2M | 99.8M | 99.4M | 99.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $72.2M | $85.4M | $69.1M | $21.8M | $49.4M | $224.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $2.49B | $2.50B | $2.76B | $2.81B | $3.32B | $3.34B |
| Total assets | $7.09B | $6.53B | $6.10B | $5.64B | $6.86B | $6.45B |
| Total liabilities | $3.81B | $3.69B | $3.81B | $3.77B | $4.47B | $4.44B |
| Shareholders' equity | $3.28B | $2.79B | $2.26B | $1.83B | $2.36B | $1.97B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology